BD Announces CE Marking of BD ProbeTec™ Qx Amplified Assays to Improve Detection of Chlamydia trachomatis and Neisseria g...(atories total system integrity that help...),Health

The fully automated system processes up to 736 patient samples in a single work shift. It offers the least hands-on time for setup, sample extraction, workflow and maintenance. One operator can fully execute all of the functions required to report results with several BD Viper Systems operating concurrently.

The World Health Organization estimates that 92 million new cases of Chlamydia and 62 million new cases of gonorrhea are diagnosed each year.1 Genital Chlamydia is the most commonly diagnosed sexually transmitted infection in genitor-urinary medicine clinics in the United Kingdom. In 2006, there were more than 113,500 cases of uncomplicated infection, a rise of four percent from 2005.2 The detection of Chlamydia infection has risen steadily in men and women since the mid-1990s, due mainly to increased testing and improved diagnostic tests. Rates of gonococcal infection have declined in both men and women since 2003, with an overall drop of one percent (19,248 to 19,007) in 2006.

About BD ProbeTec Qx Assays and the BD Viper System with XTR Technology
The new BD Viper System with XTR Technology is designed to provide high-volume customers with highly reliable detection of Chlamydia and gonorrhea at a high throughput rate using an internal extraction control and process verification. When tested with the BD Viper System with XTR Technology, the BD ProbeTec CT Qx and GC Qx Amplified DNA Assays use BD proprietary ferric oxide, FOX™ Extraction, and Strand Displacement Amplification technologies for the direct, qualitative detection of Chlamydia trachomatis and Neisseria gonorrhoeae DNA. The tests are performed on clinician-collected female endocervical and male urethral swab specimens, patient-collected vaginal swab specimens (in a clinical setting), and male and female urine specimens. These assays are indicated for use with
'/>"/>